| Date | Title | Description |
| 20.05.2024 | Arecor’s Ultra Rapid Acting Insulin Proves Superiority In Phase 1 Trial | - |
| 09.05.2024 | Arecor And Medtronic Establish Exciting Collaboration | - |
| 12.03.2024 | ARECOR AND TRx BIOSCIENCES ESTABLISH RESEARCH COLLABORATION TO DEVELOP ORAL GLP-1 WITH ENHANCED BIOAVAILABILITY | - |
| 11.10.2022 | Headline results from Phase I clinical trial of ultra-rapid acting insulin candidate AT247 demonstrate significantly accelerated insulin absorption and early exposure compared to gold standard insulin... | Arecor Therapeutics plc
(“Arecor”, the “Company” or the “Group”)
HEADLINE RESULTS FROM PHASE I CLINICAL TRIAL OF ULTRA-RAPID ACTING INSULIN CANDIDATE AT247 DEMONSTRATE SIGNIFICANTLY ACCELERATED INSULIN ABSORPTION AND EARLY EXPOSURE COMPARED... |
| 01.08.2022 | Arecor Therapeutics raising £6m to acquire diabetes medicine specialist Tetris Pharma | - |
| 14.07.2022 | BUSINESS UPDATE | Arecor Therapeutics plc
(“Arecor” or the “Group”)
BUSINESS UPDATE Pipeline for future revenue generating partnered collaborations is strong with further deals anticipated in H2 and beyondKey data for ultra-rapid acting insulin AT247 expecte... |
| 18.05.2022 | ARECOR TO HOST KOL WEBINAR ON THE NEED FOR CONCENTRATED AND RAPID ACTING INSULIN TREATMENTS IN DIABETES CARE | Arecor Therapeutics plc
(“Arecor” or the “Group”)
ARECOR TO HOST KOL WEBINAR ON THE NEED FOR CONCENTRATED AND RAPID ACTING INSULIN TREATMENTS IN DIABETES CARE
Cambridge, UK, 18 May 2022: Arecor Therapeutics plc (AIM: AREC), the biopharmaceu... |
| 28.04.2022 | ARECOR PRESENTS FULL DATA FROM POSITIVE PHASE I CLINICAL TRIAL OF AT278 ULTRA-CONCENTRATED ULTRA-RAPID ACTING INSULIN FOR DIABETES AT ATTD MEETING | ARECOR PRESENTS FULL DATA FROM POSITIVE PHASE I CLINICAL TRIAL OF
AT278 ULTRA-CONCENTRATED ULTRA-RAPID ACTING INSULIN FOR DIABETES AT ATTD MEETING Demonstrates best-in-class potential for effective disease management in patients requiring h... |
| 12.04.2022 | Arecor Announces Oral Presentation at Attd 2022 of Phase i Clinical Trial of At278 Ultra-Concentrated Ultra-Rapid Acting Insulin for Diabetes | Arecor Therapeutics plc
(“Arecor” or the “Group”)
ARECOR ANNOUNCES ORAL PRESENTATION AT ATTD 2022 OF
PHASE I CLINICAL TRIAL OF AT278 ULTRA-CONCENTRATED ULTRA-RAPID ACTING INSULIN FOR DIABETES
Cambridge, UK, 12 April 2022: Arecor Therapeutic... |
| 23.03.2022 | ARECOR GRANTED KEY U.S. PATENT PROTECTING PROPRIETARY INSULIN PRODUCTS | Arecor Therapeutics plc
(“Arecor” or the “Group”)
ARECOR GRANTED KEY U.S. PATENT PROTECTING PROPRIETARY INSULIN PRODUCTS
Further strengthens the Company’s extensive patent portfolio protecting its proprietary Arestat™ technology and diabete... |
| 20.01.2022 | ARECOR COMMENCES US PHASE I CLINICAL TRIAL OF AT247 ULTRA-RAPID INSULIN IN COMBINATION WITH AN INSULIN PUMP | Arecor Therapeutics plc
(“Arecor” or the “Group”)
ARECOR COMMENCES US PHASE I CLINICAL TRIAL OF AT247 ULTRA-RAPID INSULIN IN COMBINATION WITH AN INSULIN PUMP
First patient dosed in potential game-changing diabetes combination therapy
Cambri... |
| 20.01.2022 | BUSINESS UPDATE | Arecor Therapeutics plc
(“Arecor”, the “Company” or the “Group”)
BUSINESS UPDATE
Momentum continues across partnered and proprietary portfolio
Cambridge, UK, 20 January 2022: Arecor Therapeutics plc (AIM: AREC), a globally focused biopharma... |
| 20.01.2022 | ARECOR COMMENCES US PHASE I CLINICAL TRIAL OF AT247 ULTRA-RAPID INSULIN IN COMBINATION WITH AN INSULIN PUMP | Arecor Therapeutics plc
(“Arecor” or the “Group”)
ARECOR COMMENCES US PHASE I CLINICAL TRIAL OF AT247 ULTRA-RAPID INSULIN IN COMBINATION WITH AN INSULIN PUMP
First patient dosed in potential game-changing diabetes combination therapy
Cambri... |
| 14.12.2021 | Arecor announces exclusive collaboration with global technology leader | Arecor announces exclusive collaboration with global technology leader
14-12-2021
Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today’s therapies to enable healthier lives, today announces that it has signed an ... |
| 11.11.2021 | Arecor granted key Canadian patent for proprietary technology enabling highly concentrated biotherapeutics | Arecor granted key Canadian patent for proprietary technology enabling highly concentrated biotherapeutics
11-11-2021
Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today’s therapies to enable healthier lives, co... |
| 01.11.2021 | ARECOR ANNOUNCES AN EXCLUSIVE FORMULATION STUDY COLLABORATION WITH A LEADING GLOBAL MEDICAL PRODUCTS COMPANY TO DEVELOP A STABLE READY TO ADMINISTER PRODUCT | Arecor Therapeutics plc
(“Arecor” or the “Group”)
ARECOR ANNOUNCES AN EXCLUSIVE FORMULATION STUDY COLLABORATION WITH
A LEADING GLOBAL MEDICAL PRODUCTS COMPANY TO DEVELOP A STABLE READY TO ADMINISTER PRODUCT
Cambridge, UK, 1 November 2021: A... |
| 01.11.2021 | Arecor announces exclusive collaboration with leading global medical products company | Arecor announces exclusive collaboration with leading global medical products company
01-11-2021
Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today’s therapies to enable healthier lives, today announces that it... |
| 20.09.2021 | Arecor announces positive headline results from first Phase I clinical trial of diabetes treatment | Arecor announces positive headline results from first Phase I clinical trial of diabetes treatment
20-09-2021
Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical company advancing today’s therapies to enable healthier lives, today an... |
| 20.09.2021 | Arecor announces positive headline results from first Phase I clinical trial of diabetes treatment | Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces that its ultra-concentrated ultra-rapid acting insulin, AT278 met all of its primary and secondary end... |
| 20.09.2021 | Arecor Announces Positive Headline Results From First Phase i Clinical Trial of At278 Ultra-Concentrated Ultra-Rapid Acting Insulin Candidate for Diabetes | Arecor Therapeutics plc
(“Arecor”, the “Company” or the “Group”)
ARECOR ANNOUNCES POSITIVE HEADLINE RESULTS FROM FIRST PHASE I CLINICAL TRIAL OF AT278 ULTRA-CONCENTRATED ULTRA-RAPID ACTING INSULIN CANDIDATE FOR DIABETES AT278 delivers signi... |
| 27.08.2021 | Arecor announces appointment of Grant Thornton as auditor | Arecor announces appointment of Grant Thornton as auditor
27-08-2021
Arecor Therapeutics plc (AIM: AREC), a globally focused biopharmaceutical group advancing today’s therapies to enable healthier lives, announces that Grant Thornton UK LLP... |
| 27.08.2021 | Arecor announces appointment of Grant Thornton as auditor | Arecor Therapeutics plc (AIM: AREC), a globally focused biopharmaceutical group advancing today’s therapies to enable healthier lives, announces that Grant Thornton UK LLP has been appointed as the Group’s auditor, with immediate effect. La... |
| 07.06.2021 | Arecor announces exclusive formulation study collaboration with Par | Arecor announces exclusive formulation study collaboration with Par
07-06-2021
Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces that it has signed a fo... |
| 03.06.2021 | Arecor market cap soars to c$100m after IPO | Arecor market cap soars to c$100m after IPO
03-06-2021
Cambridge biopharma business Arecor made a stunning bow on London’s AIM market today as its share price immediately grew wings.
At one stage in the early flurry of dealings the market c... |
| 20.05.2021 | Arecor Announces an Exclusive Formulation Study Collaboration With Lilly | CAMBRIDGE, United Kingdom, May 20, 2021 (GLOBE NEWSWIRE) -- Arecor Limited (“Arecor” or “the Company”), the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces that it has signed a formulation st... |
| 31.03.2021 | Arecor receives £2.8 million grant award from Innovate UK | Arecor Limited, the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces that it has been awarded a £2.8 million grant from Innovate UK to support the Phase II development of AT247, its ultra-rapi... |
| 31.03.2021 | Arecor receives £2.8 million grant award from Innovate UK | Arecor receives £2.8 million grant award from Innovate UK
31-03-2021
Arecor Limited, the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces that it has been awarded a £2.8 million grant from Inn... |
| 31.03.2021 | Arecor Receives £2.8 Million Grant Award From Innovate UK | CAMBRIDGE, United Kingdom, March 31, 2021 (GLOBE NEWSWIRE) -- Arecor Limited ("Arecor" or "the Company"), the biopharmaceutical company advancing today's therapies to enable healthier lives, today announces that it has b... |
| 17.12.2020 | Arecor’s partner Inhibrx exercises its option to license a new formulation | Arecor’s partner Inhibrx exercises its option to license a new formulation
17-12-2020
Arecor Ltd , the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces that its partner, Inhibrx, Inc., has exe... |
| 16.12.2020 | Arecor announces publication of Phase I data for AT247 in diabetes care | Arecor Limited,, the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces that Diabetes Care has published data for the Phase I clinical trial of AT247, its ultra-rapid acting insulin product cand... |
| 16.12.2020 | Arecor announces publication of Phase I data for AT247 in diabetes care | Arecor announces publication of Phase I data for AT247 in diabetes care
16-12-2020
Arecor Limited,, the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces that Diabetes Care has published data f... |
| 15.06.2020 | ARECOR presents positive results for the first Phase I clinical trial of novel insulin formulation | ARECOR presents positive results for the first Phase I clinical trial of novel insulin formulation
15-06-2020
AT247 delivers significantly accelerated absorption of insulin compared to best in class treatments NovoRapid® and Fiasp®.
Arecor ... |
| 19.03.2020 | Arecor extends multi-product collaboration with clinical stage biotech | Arecor extends multi-product collaboration with clinical stage biotech
19-03-2020
Arecor Limited, the biopharmaceutical company advancing today’s therapies to enable healthier lives, announces that it has extended its multi-product collabor... |
| 25.02.2020 | Arecor achieves second licence milestone payment from global pharmaceutical partner | Arecor achieves second licence milestone payment from global pharmaceutical partner
25-02-2020
Arecor Ltd, the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces that it has achieved an importan... |
| 05.12.2019 | Arecor announces positive headline results for first Phase I clinical trial of AT247, a novel formulation of insulin | Arecor Limited, the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces positive headline results for the Phase I clinical trial of its ultra-rapid acting insulin product candidate, AT247.
In the... |
| 05.12.2019 | Arecor announces positive headline results for first Phase I clinical trial of AT247, a novel formulation of insulin | Arecor announces positive headline results for first Phase I clinical trial of AT247, a novel formulation of insulin
05-12-2019
Arecor Limited, the biopharmaceutical company advancing today’s therapies to enable healthier lives, today annou... |
| 22.10.2019 | Arecor and JDRF sign a joint research, development and commercialisation agreement | Arecor and JDRF sign a joint research, development and commercialisation agreement
22-10-2019
Arecor Ltd, the biopharmaceutical company advancing today’s therapies to enable healthier lives, announces that it has signed a Research, Developm... |
| 03.05.2019 | Arecor signs new multi-product collaboration with major global pharmaceutical company | Arecor signs new multi-product collaboration with major global pharmaceutical company
03-05-2019
Arecor Limited, the specialty pharmaceutical company leveraging its innovative and proprietary formulation technology, Arestat(TM), to develop ... |
| 11.03.2019 | Arecor appoints Chief Financial Officer | Arecor appoints Chief Financial Officer
11-03-2019
Arecor Limited, the specialty pharmaceutical company leveraging its innovative and proprietary formulation technology to develop superior treatments for a range of disease areas, including ... |
| 13.02.2019 | Super-fast-acting prandial insulin product receives £0.5m Innovate UK boost | Arecor Ltd, the specialty pharmaceutical company leveraging its innovative and proprietary formulation technology to develop superior treatments for a range of disease areas, including diabetes, is pleased to announce that it has been award... |
| 13.02.2019 | Super-fast-acting prandial insulin product receives £0.5m Innovate UK boost | Super-fast-acting prandial insulin product receives £0.5m Innovate UK boost
13-02-2019
Arecor Ltd, the specialty pharmaceutical company leveraging its innovative and proprietary formulation technology to develop superior treatments for a ra... |
| 10.01.2019 | Arecor participates in PepTalk 2019’s Protein Science week in San Diego, CA, USA | Arecor participates in PepTalk 2019’s Protein Science week in San Diego, CA, USA
10-01-2019
Arecor Limited is pleased to announce its participation at PEPTalk 2019’s Protein Science Week. This leading international conference and one of the... |
| 14.12.2018 | Arecor attends the 37TH annual JP Morgan Healthcare Conference | Arecor attends the 37TH annual JP Morgan Healthcare Conference
14-12-2018
Arecor Ltd, the UK-based specialty pharmaceutical company that develops superior biopharmaceuticals through the application of an innovative formulation technology pl... |
| 31.10.2018 | Arecor successfully defends a key European Patent | Arecor successfully defends a key European Patent
31-10-2018
Arecor successfully defends a key European patent in opposition proceedings on the subject of mitigation of aggregation of therapeutic proteins during storage.
Arecor Ltd, the UK-... |
| 11.09.2018 | Biopharma Formulation Company Arecor Raises £6M | Arecor, a Chesterford Research Park, Little Chesterford, Saffron Walden, UK-based biopharmaceutical formulation company, raised £6m in funding.
The round was led by Calculus Capital with participation from Albion Capital and Downing Venture... |
| 10.09.2018 | Arecor secures £6m investment for clinical development of its diabetes portfolio | Arecor secures £6m investment for clinical development of its diabetes portfolio
10-09-2018
Arecor Ltd, the UK-based leader in developing superior biopharmaceuticals through the application of an innovative formulation technology platform, ... |
| 18.06.2018 | Arecor secures grant to advance co-formulation of critical pharmaceutical products | Arecor secures grant to advance co-formulation of critical pharmaceutical products
18-06-2018
Innovate UK grant of nearly £1 million will be used to significantly advance Arecor’s proprietary co-formulation platform in the development of di... |
| 18.06.2018 | Arecor secures grant to advance co-formulation of critical pharmaceutical products | Innovate UK grant of nearly £1 million will be used to significantly advance Arecor’s proprietary co-formulation platform in the development of diabetes therapies that meet critical patient unmet needs.
Arecor Ltd, a leader in developing su... |
| 10.01.2018 | Arecor launches new website | Arecor launches new website
10-01-2018
Arecor Ltd, the leading formulation technology company focused on developing superior biopharmaceuticals via the innovative reformulation of proteins and peptides to improve the treatment of diabetes a... |
| 10.01.2018 | Arecor launches new website | Arecor Ltd, the leading formulation technology company focused on developing superior biopharmaceuticals via the innovative reformulation of proteins and peptides to improve the treatment of diabetes and other conditions, is pleased to anno... |
| 08.01.2018 | European patent on the horizon for Arecor’s proprietary technology | European patent on the horizon for Arecor’s proprietary technology
08-01-2018
Arecor Ltd is pleased to announce the European Patent Office (EPO) has issued “Notice of Intention to Grant” for Arecor’s patent application protecting the Compan... |
| 04.01.2018 | Arecor and JDRF announce successful pre-clinical development of diabetes treatment | Arecor and JDRF announce successful pre-clinical development of diabetes treatment
04-01-2018
Arecor and JDRF announce the successful pre-clinical development of stable rapid-acting, ultra-concentrated insulin for the significantly enhanced... |
| 03.10.2017 | Arecor announces license agreement with global pharmaceutical company | Arecor announces license agreement with global pharmaceutical company
03-10-2017
Arecor Ltd (“the Company”), the leading formulation technology company, focussed on developing superior biopharmaceuticals via the innovative reformulation of ... |
| 12.09.2017 | Arecor announces the inaugural formation of a global diabetes Scientific Advisory Board | Arecor announces the inaugural formation of a global diabetes Scientific Advisory Board
12-09-2017
Arecor Ltd, the leading formulation technology company, focused on developing superior biopharmaceuticals to improve the treatment of diabete... |
| 25.07.2016 | Arecor partners with JDRF to develop novel diabetes treatment | Arecor partners with JDRF to develop novel diabetes treatment
25-07-2016
JDRF announces partnership with Arecor Ltd to support development of a stable, rapid-acting, ultra-concentrated insulin.
Improved insulins would enable the miniaturiza... |
| 12.11.2015 | Arecor, CPI and FUJIFILM Diosynth Biotechnologies collaborate | Arecor, CPI and FUJIFILM Diosynth Biotechnologies collaborate
12-11-2015
Arecor, CPI and FUJIFILM Diosynth Biotechnologies collaborate to apply smart formulation approaches in the manufacturing of biopharmaceuticals under a grant awarded by... |
| 12.06.2015 | Arecor CEO announces resignation | Arecor CEO announces resignation
12-06-2015
Thomas Saylor is retiring as CEO of Arecor, the position in which he has effectively served for the past eight years.
Although Tom has decided to retire from full time responsibility as CEO he has... |
| 12.06.2015 | Arecor CEO announces resignation | Thomas Saylor is retiring as CEO of Arecor, the position in which he has effectively served for the past eight years.
Although Tom has decided to retire from full time responsibility as CEO he has been asked by the Board to remain as a non-... |
| 31.07.2014 | Arecor awarded TSB grant to support expanded protein stability platform | Arecor awarded TSB grant to support expanded protein stability platform
31-07-2014
Arecor Limited has been awarded a prestigious Technology Strategy Board (TSB) grant to apply its proprietary technology for developing stable formulations of... |
| 24.06.2014 | GALVmed-Arecor collaborate to pursue new vaccine formulations for developing world livestock | GALVmed-Arecor collaborate to pursue new vaccine formulations for developing world livestock
24-06-2014
New vaccine formulations to combat two major diseases of livestock in the developing world are to be pursued through a partnership betwe... |
| 18.06.2014 | CPI collaborate with Arecor to enhance compatibility of biologic medicines with containers | CPI collaborate with Arecor to enhance compatibility of biologic medicines with containers
18-06-2014
The Centre for Process Innovation (CPI) is working with Arecor to enhance the compatibility of biologic medicines with containers, and the... |
| 29.10.2013 | Arecor launches new platform tool for viscosity reduction in high concentration biologics | Arecor launches new platform tool for viscosity reduction in high concentration biologics
29-10-2013
Arecor, the Cambridge biotechnology company specialising in the stabilisation of biopharmaceuticals, announced today a key addition to its ... |
| 29.10.2013 | Arecor launches new platform tool for viscosity reduction in high concentration biologics | Arecor, the Cambridge biotechnology company specialising in the stabilisation of biopharmaceuticals, announced today a key addition to its Arestat(TM) platform, through the creation of a novel and proprietary formulation design tool to redu... |
| 16.07.2013 | Arecor granted key US patent for metalloprotein stabilisation | Arecor granted key US patent for metalloprotein stabilisation
16-07-2013
Arecor, the Cambridge biotechnology company specialising in the stabilisation of biopharmaceuticals, announced today the granting of US Patent No. 8486388, which prote... |
| 25.04.2013 | Arecor patents ground breaking heat stable adenovirus vaccine technology | Arecor patents ground breaking heat stable adenovirus vaccine technology
25-04-2013
Arecor announces today a significant leap forward to enabling liquid-stable versions of live-virus containing products, used widely in vaccines and gene the... |
| 29.03.2013 | Science Minister David Willetts visits Arecor | Science Minister David Willetts visits Arecor
29-03-2013
Science Minister David Willetts this week visited Arecor to learn more about its pioneering projects after being awarded £785,000 under the government-backed Biomedical Catalyst to ac... |
| - | BGF explains: our approach to quoted investments | BGF, which has invested in public markets since 2014, has seen a significant step up in activity since 2016. With a consistent focus on the smaller end of the market, quoted companies, alongside privately held ones, are an essential part of... |
| - | The time to put the spotlight on Healthcare is now | As Covid-19 continues to dominate the global agenda, early-stage UK technology companies in the healthcare and life sciences sectors are at the forefront of making the world a safer and more secure place to live in.
The need for accelera... |
| - | First Day of Dealings on AIM for Arecor | We are delighted to share Arecor's announcement of its first day of dealings on AIM.
Arecor is part of the Downing Healthcare EIS portfolio and Downing FOUR VCT.
Arecor Therapeutics plc, a globally focused biopharmaceutical company that i... |
